Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

<p>Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide</p>
Bryce C. Simes, Gordon G. MacGregor
Diabetes Metabolic Syndrome and Obesity (2019) Vol. Volume 12, pp. 2125-2136
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes
W. David Strain, Su Down, Pam Brown, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 5, pp. 1227-1247
Open Access | Times Cited: 129
Research progress on the hypoglycemic activity and mechanisms of natural polysaccharides
Hongkun Xue, Zitong Hao, Yuchao Gao, et al.
International Journal of Biological Macromolecules (2023) Vol. 252, pp. 126199-126199
Closed Access | Times Cited: 60
Adherence to Oral Antidiabetic Drugs in Patients with Type 2 Diabetes: Systematic Review and Meta-Analysis
Eugenia Piragine, Davide Petri, Alma Martelli, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1981-1981
Open Access | Times Cited: 33
Interference With the AMPKα/mTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effectively Protects Against the Dextran Sulfate Sodium Intoxication in Rats: A New Paradigm in Empagliflozin and Metformin Reprofiling for the Management of Ulcerative Colitis
Mahmoud E. Youssef, Eslam E. Abd El-Fattah, A. M. Abdelhamid, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 46
SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
Daria M. Keller, Natasha Ahmed, Hamza Tariq, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 6, pp. 1470-1470
Open Access | Times Cited: 33
Bridging the gap: glucose transporters, Alzheimer’s, and future therapeutic prospects
Mai Albaik, Dalaa Sheikh Saleh, Dana Kauther, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 7
Development and Validation of Rapid RP-HPLC and Green Second-Derivative UV Spectroscopic Methods for Simultaneous Quantification of Metformin and Remogliflozin in Formulation Using Experimental Design
Mahesh Attimarad, Rafea Elamin Elgack Elgorashe, Rajasekaran Subramaniam, et al.
Separations (2020) Vol. 7, Iss. 4, pp. 59-59
Open Access | Times Cited: 40
Diabetes education in pediatrics: How to survive diabetes
Berrin Ergun-Longmire, Ethel Gonzales Clemente, Patricia Vining-Maravolo, et al.
Disease-a-Month (2021) Vol. 67, Iss. 8, pp. 101153-101153
Closed Access | Times Cited: 38
Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice
Kamlesh Khunti, Serge Jabbour, Xavier Cos, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 7, pp. 1187-1196
Open Access | Times Cited: 27
SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure
Rahul Gupta, Theresa Maitz, David Egeler, et al.
Trends in Cardiovascular Medicine (2022) Vol. 33, Iss. 8, pp. 479-486
Closed Access | Times Cited: 20
Developing the Theory of Toxic Chemotherapeutic Nutrition for Cancer Cells and Targeting Tumors via Glucose Mutation: Medical Guidance and Integrated Therapeutic Approach
Maher M. Akl, Amr Ahmed
(2024)
Open Access | Times Cited: 4
Bitter gourd (Momordica charantia L.) supplementation for twelve weeks improves biomarkers of glucose homeostasis in a prediabetic population.
Jurriaan J. Mes, Maartje van den Belt, Sandra van der Haar, et al.
Journal of Ethnopharmacology (2025), pp. 119756-119756
Open Access
Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment
Barbara Gieroba, Adrianna Kryska, Anna Sroka‐Bartnicka
Biochemistry and Biophysics Reports (2025) Vol. 42, pp. 102037-102037
Closed Access
Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
Mariusz Dąbrowski
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1680-1680
Open Access | Times Cited: 27
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs
Andreas P. Katsenos, Athena S. Davri, Yannis V. Simos, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 1, pp. 105-123
Closed Access | Times Cited: 27
Canagliflozin and Dapagliflozin Attenuate Glucolipotoxicity-Induced Oxidative Stress and Apoptosis in Cardiomyocytes via Inhibition of Sodium-Glucose Cotransporter-1
Deepika Dasari, Audesh Bhat, Sureshbabu Mangali, et al.
ACS Pharmacology & Translational Science (2022) Vol. 5, Iss. 4, pp. 216-225
Open Access | Times Cited: 18
A Drug Safety Evaluation of Dapagliflozin for Diabetic Nephropathies in Patients with Cardiovascular Risk
Aayushi Sood, Aanchal Sawhney, Benjamin Borokhovsky, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Boosting amygdaloid GABAergic and neurotrophic machinery via dapagliflozin-enhanced LKB1/AMPK signaling in anxious demented rats
Ahmed S. Kamel, Ahmed Wahid, Noha F. Abdelkader, et al.
Life Sciences (2022) Vol. 310, pp. 121002-121002
Closed Access | Times Cited: 15
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence
Koichi Yabiku
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 18
Novel and emerging therapeutic drug targets for management of type 2 Diabetes Mellitus
Prateek Sharma, Sukhbir Singh, Vinay Thakur, et al.
Obesity Medicine (2021) Vol. 23, pp. 100329-100329
Closed Access | Times Cited: 17
Canagliflozin Prevents Hyperglycemia-Associated Muscle Extracellular Matrix Accumulation and Improves the Adaptive Response to Aerobic Exercise
Tara MacDonald, Pattarawan Pattamaprapanont, Eileen M. Cooney, et al.
Diabetes (2022) Vol. 71, Iss. 5, pp. 881-893
Open Access | Times Cited: 12
SGLT2 inhibitors for the treatment of diabetes: a patent review (2019–23)
Rahul Baghel, Nikita Chhikara, Pawan Kumar, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 9, pp. 807-823
Closed Access | Times Cited: 2
Diabetes and skin cancers: Risk factors, molecular mechanisms and impact on prognosis
Elena-Codruța Dobrică, Madalina Laura Banciu, Vincent Kipkorir, et al.
World Journal of Clinical Cases (2022) Vol. 10, Iss. 31, pp. 11214-11225
Open Access | Times Cited: 10
Sodium-glucose co-transporter 2 inhibitor canagliflozin modulates myocardial metabolism and inflammation in a swine model for chronic myocardial ischemia
Dwight D. Harris, Sharif A. Sabe, Cynthia Xu, et al.
Surgery (2023) Vol. 175, Iss. 2, pp. 265-270
Closed Access | Times Cited: 6
Current concept in the diagnosis, treatment and rehabilitation of patients with congestive heart failure
Ivana Sopek Merkaš, Ana Marija Slišković, Nenad Lakušić
World Journal of Cardiology (2021) Vol. 13, Iss. 7, pp. 183-203
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top